The Value of a Risk Prediction Tool (PERSARC) for Effective Treatment Decisions of Soft-tissue Sarcomas Patients

NAActive, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 24, 2021

Primary Completion Date

August 29, 2024

Study Completion Date

August 29, 2025

Conditions
Soft-tissue SarcomaPredictive Cancer Model
Interventions
OTHER

Care with the use of PERSARC

PERSARC is a personalized risk assessment tool which provides patients and STS professionals insight into the personalized risks and benefits of each treatment option based on patient's age, tumor size, tumor depth and histology. PERSARC will be used in multidisciplinary tumour boards to guide treatment advice and in consultation in which the oncological/orthopaedic surgeon informs the patient about his/her diagnoses and discusses the benefits and harms of all relevant treatment options

OTHER

standard care

All patients in control condition receive usual care.

Trial Locations (7)

6525GA

Radboud UMC, Nijmegen

6229HX

Maastricht UMC, Maastricht

1066CX

Netherlands Cancer Institue, Amsterdam

9713GZ

UMC Groningen, Groningen

2333ZA

Leiden University Medical Center, Leiden

3015GD

Erasmus MC, Rotterdam

3584CX

UMC Utrecht, Utrecht

All Listed Sponsors
lead

Leiden University Medical Center

OTHER